Loading
quaratusugene ozeplasmid / Atezolizumab / Small Cell Lung Cancer Extensive Stage · Phase 1/2 Trial
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 1/2 study of quaratusugene ozeplasmid combined with atezolizumab maintenance therapy in extensive-stage small cell lung cancer. The trial is currently recruiting and has not yet published results; no efficacy or safety data are available from this registry record.
Phase 1/2, Interventional, Non Randomized, Sequential, Open label, Treatment purpose. Small Cell Lung Cancer Extensive Stage; age from 18 Years. Intervention: Phase 1; Phase 2. n = 62. 17 sites: United States.
This is a planned Phase 1/2 study of quaratusugene ozeplasmid combined with atezolizumab maintenance therapy in extensive-stage small cell lung cancer. The trial is currently recruiting and has not yet published results; no efficacy or safety data are available from this registry record.
This is a registry record with no posted results; no efficacy, safety, or tolerability data are available.
Once results are available, this trial will inform the tolerability and preliminary efficacy of this combination approach in a poor-prognosis population. Clinicians should monitor ClinicalTrials.gov for publication of Phase 1 dose-finding and Phase 2 efficacy data.
This is a clinical trial registry record describing a Phase 1/2 study that is actively recruiting with no results yet posted; it represents early-stage evaluation of a novel combination therapy.
As stated by the source record.
Quoted from the source exactly as published.
Once results are available, this trial will inform the tolerability and preliminary efficacy of this combination approach in a poor-prognosis population. Clinicians should monitor ClinicalTrials.gov for publication of Phase 1 dose-finding and Phase 2 efficacy data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05703971). This is a study registration, not published results. Lead sponsor: Genprex, Inc.. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 62 participants (ESTIMATED). Conditions: Small Cell Lung Cancer Extensive Stage. Interventions: BIOLOGICAL: quaratusugene ozeplasmid; BIOLOGICAL: atezolizumab. Primary outcome measures: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) - Phase 1 , First 21-days at each dose level; Progression-Free Survival Rate (PFSR) - Phase 2 , 18-weeks from Day 1 of maintenance therapy. Brief summary: This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.